Gene Therapy Market by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy), Vector Type (Non-viral Vectors, Viral Vectors), Application - Global Forecast 2024-2030

Gene Therapy Market by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy), Vector Type (Non-viral Vectors, Viral Vectors), Application - Global Forecast 2024-2030

The Gene Therapy Market size was estimated at USD 5.67 billion in 2023 and expected to reach USD 7.05 billion in 2024, at a CAGR 27.15% to reach USD 30.48 billion by 2030.

Gene therapy is a medical procedure that introduces, alters, or corrects genetic material within an individual's cells to treat or prevent disease. The primary purpose of gene therapy is to address genetic disorders by replacing or repairing faulty genes, introducing therapeutic genes, or regulating the expression of genes. This field holds great promise for treating various genetic and acquired diseases at their root cause. Several factors are contributing to the growth of the gene therapy market, including an increase in the prevalence of chronic conditions, a rise in acceptance of gene therapy treatment, a surge in clinical trials, and escalated R&D expenditure in the pharmaceutical sector. However, the cost of these therapies is exceptionally high, accompanied by a complex and lengthy development process. Additionally, concerns regarding off-target effects, immunogenicity, and long-term safety may hamper its market demand. Moreover, advanced technology development has opened several previously inaccessible gene editing and therapy frontiers. The gene therapy market is anticipated to grow further due to regulatory authorities' rising approval of gene therapy products, which brought forth many potential opportunities with targeted disease treatments.

Regional Insights

The Americas has a significant landscape in gene therapy owing to rising research and innovation with significant investments in this domain. The gene therapy market has witnessed exponential growth, mainly due to the improved prevalence of chronic diseases, availability of funding for genetic research, a strong presence of industry players, and FDA approvals that significantly impact gene therapy trends. The European region shows considerable growth in the gene therapy sector due to advanced research in gene therapy due to its well-established pharmaceutical companies. The European Union invests heavily in healthcare research, including gene therapy. Countries lead in therapeutic clinical trials, particularly in oncology, cardiovascular, and inherited diseases. The Asia-Pacific region is a rapidly emerging market in the arena of gene therapy. The surge in clinical trials spurred by its burgeoning biotech sector and substantial government funding, fast-track innovative gene therapy research is further fueled by expanded market demand. Overall, the APAC region's growth in gene therapy is driven by a combination of large patient populations, growing healthcare expenditure, and evolving regulatory environments.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Gene Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
    • Government Support and Ethical Acceptance of Gene Therapy For Treatments
    • Market Restraints
      • High Costs Associated with Gene Therapies
      • Market Opportunities
        • Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
        • Innovative Payment Models and Favorable Regulatory Approvals
        • Market Challenges
          • Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy
          • Market Segmentation Analysis
            • Type: Prevalence of cancer gene therapy for cancer treatment
            • Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells
            • Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Gene Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Gene Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
              
              Charles River introduced the Lentivation Platform to expedite the development of lentiviral-based gene therapies. This innovative platform empowers scientists with enhanced control over transgene expression, ensuring better safety and efficacy for gene therapy products. With the Lentivation Platform, researchers can stress the importance of transgene regulation, leading to improved outcomes in gene therapy treatments. This technology represents a significant advancement in gene therapy, offering a promising solution for addressing various genetic disorders and diseases.
              
              Laurus to launch Gene Therapy Assets in India
              
              Laurus Labs introduced gene therapy-based assets in India, offering treatment options for retinal and muscular dystrophy. This development signifies the entry of the genetic medicine market in India, with industry experts anticipating significant opportunities in the field of gene therapy.
              
              Bluebird bio Lays Gene Therapy Launch Groundwork As Sickle Cell Application Nears
              
              Bluebird Bio launched Zynteglo, its dual gene therapy. Gene therapy is a rapidly expanding medical research and treatment field, with Zynteglo offering potential cures for previously untreatable genetic diseases. This groundbreaking therapy brings hope to patients and opens up new possibilities in the fight against genetic disorders.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Gene Therapy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, AGC Biologics., Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Applied Genetic Technologies Corporation, Astellas Gene Therapies, Biogen Inc., Bluebird Bio, Inc., Cellectis, Inc., Editas Medicine, Inc., Human Stem Cells Institute, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Mustang Bio, Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics, Inc., and Uniqure N.V..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Type
              • Antigen Gene Therapy
              • Cancer Gene Therapy
              • Cytokine Gene Therapy
              • Suicide Gene Therapy
              • Tumor Suppressor Gene Therapy
              • Vector Type
                • Non-viral Vectors
                • Viral Vectors
                • Application
                  • Cardiovascular Diseases
                  • Genetic Diseases
                  • Infectious Diseases
                  • Neurological Diseases
                  • Oncological Disorders
                  • Region
                    • Americas
                      • Argentina
                      • Brazil
                      • Canada
                      • Mexico
                      • United States
                        • California
                        • Florida
                        • Illinois
                        • New York
                        • Ohio
                        • Pennsylvania
                        • Texas
                        • Asia-Pacific
                          • Australia
                          • China
                          • India
                          • Indonesia
                          • Japan
                          • Malaysia
                          • Philippines
                          • Singapore
                          • South Korea
                          • Taiwan
                          • Thailand
                          • Vietnam
                          • Europe, Middle East & Africa
                            • Denmark
                            • Egypt
                            • Finland
                            • France
                            • Germany
                            • Israel
                            • Italy
                            • Netherlands
                            • Nigeria
                            • Norway
                            • Poland
                            • Qatar
                            • Russia
                            • Saudi Arabia
                            • South Africa
                            • Spain
                            • Sweden
                            • Switzerland
                            • Turkey
                            • United Arab Emirates
                            • United Kingdom
                            
                            
                            Please Note: PDF & Excel + Online Access - 1 Year